#United States #Los Angeles #Ultrasound Technology #prenatal care #Pulsenmore

Pulsenmore's First Commercial Engagement in the U.S.

Pulsenmore Ltd., a frontrunner in home ultrasound technologies, has made headlines with its announcement of a first commercial collaboration in the United States. This significant advancement follows its acquisition of FDA approval for a home pregnancy ultrasound product. As of January 2026, through its subsidiary, Pulsenmore entered into a services agreement with the Center for Fetal Medicine and Women’s Ultrasound (CFFM), a specialized facility located in Los Angeles, California.

This pivotal agreement allows CFFM to procure Pulsenmore's innovative ES home ultrasound services. The integration of this service is expected to transform patient experiences by providing the convenience of remote monitoring, thereby reducing unnecessary trips to medical facilities. In today’s rapidly evolving healthcare landscape, such advancements are crucial, particularly in offering high-quality prenatal care.

Pulsenmore's home ultrasound and telehealth systems represent a significant shift in how prenatal care is delivered, addressing a growing global need for enhanced care that goes beyond traditional clinical settings. This initiative positions Pulsenmore at the forefront of digital health, telemedicine, and femtech—sectors essential for improving health outcomes for expectant mothers. With the ability to facilitate remote prenatal monitoring, Pulsenmore aims to elevate patient access and ensure continuity of care, ultimately enriching the overall patient experience.

The CFFM, known for its comprehensive prenatal diagnostics, manages about 1,500 pregnancies annually. The center’s commitment to high-risk pregnancy management underscores the importance of this collaboration. Dr. Lawrence Platt, head of CFFM, expressed optimism regarding this new partnership, stating, “Pulsenmore's ultrasound system marks a new era in maternal-fetal care, empowering expectant mothers with safe, guided access to ultrasound imaging from home or work, while ensuring that clinicians remain closely connected throughout the entire process.”

Dr. Elazar Sonnenschein, the CEO of Pulsenmore, termed this engagement a vital milestone in their U.S. strategy, signifying a notable step forward after securing FDA clearance. “The agreement with CFFM allows for the deployment of a remote pregnancy monitoring model that centers on the patient’s needs,” he commented. This approach is especially relevant in a market where many women grapple with limited access to obstetric healthcare services.

Such initiatives not only foster the integration of technology into routine medical care but also demonstrate Pulsenmore's commitment to providing patient-centric solutions. The partnership paves the way for gradually and responsibly offering home-based ultrasound options, which are becoming more essential in modern healthcare.

As Pulsenmore continues to innovate in maternal health, the focus remains on improving access to safe and effective prenatal care. By leveraging advanced imaging and telemedicine technologies, they aim to expand their reach and enhance the quality of care provided to mothers and healthcare providers alike.

For additional information regarding Pulsenmore and their groundbreaking healthcare innovations, visit www.pulsenmore.com. This partnership highlights a promising future for remote prenatal monitoring, ultimately leading to improved health outcomes for mothers and their babies across the U.S.